GlassScriptPhysician profile
Parmanand Singh
NPI 1194902437
$781.16
in general payments reported to CMS, 2019-2025
17 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $294 · 2024: $247 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $103.35 | 2023-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $86.59 | 2023-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $72.83 | 2023-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $66.22 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $65.81 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.12 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $56.90 | 2025 | Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $47.36 | 2023-2024 | Verquvo |
| Pfizer INC. | $46.56 | 2023-2024 | |
| Scpharmaceuticals INC. | $34.65 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.09 | 2024 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $27.87 | 2023 | Arcalyst |
| Abbott Laboratories | $22.74 | 2024 | Jot Dx |
| Lantheus Medical Imaging, INC. | $21.57 | 2023 | Definity |
| Janssen Pharmaceuticals, INC | $21.13 | 2023 | Xarelto |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $16.37 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parmanand Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.